Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.94 USD | -1.52% | -10.65% | -49.61% |
05-02 | Acurx Pharmaceuticals, Inc. Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global Scientific Conference | CI |
04-04 | Top Premarket Gainers | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 44.15 | 46.14 | 52.73 | 31.17 | - | - |
Enterprise Value (EV) 1 | 44.15 | 46.14 | 52.73 | 31.17 | 31.17 | 31.17 |
P/E ratio | -2.9 x | -3.55 x | -3.33 x | -2.03 x | -1.2 x | -0.89 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | 1.94 x |
EV / Revenue | - | - | - | - | - | 1.94 x |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | -3,483,532 x | - | - | - | - | - |
FCF Yield | -0% | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 10,216 | 11,593 | 13,768 | 15,823 | - | - |
Reference price 2 | 4.321 | 3.980 | 3.830 | 1.970 | 1.970 | 1.970 |
Announcement Date | 16/03/22 | 15/03/23 | 15/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 16.03 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -12.81 | -12.09 | -14.58 | -15.6 | -26.06 | -17.45 |
Operating Margin | - | - | - | - | - | - | -108.84% |
Earnings before Tax (EBT) 1 | - | -12.75 | -12.09 | -14.58 | -15.6 | -28.58 | -41.28 |
Net income 1 | -4.6 | -12.75 | -12.09 | -14.58 | -15.6 | -26.06 | -17.45 |
Net margin | - | - | - | - | - | - | -108.84% |
EPS 2 | -0.7500 | -1.490 | -1.120 | -1.150 | -0.9700 | -1.645 | -2.220 |
Free Cash Flow | - | -12.67 | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 05/04/21 | 16/03/22 | 15/03/23 | 15/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -2.627 | -2.67 | - | -3.542 | -3.261 | -2.903 | -3.445 | -3.115 | -5.115 | -3.8 | -3.2 | -2.9 | -5.7 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -2.627 | -2.67 | - | -3.542 | -3.261 | -2.903 | -3.445 | -3.115 | -5.115 | -3.8 | -3.2 | -2.9 | -5.7 |
Net income 1 | -2.627 | -2.67 | -2.621 | -3.542 | -3.261 | -2.903 | -3.445 | -3.115 | -5.115 | -3.8 | -3.2 | -2.9 | -5.7 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.2200 | -0.2600 | -0.2600 | -0.3200 | -0.2800 | -0.2500 | -0.2800 | -0.2400 | -0.3800 | -0.2400 | -0.2000 | -0.1800 | -0.3500 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 16/03/22 | 10/05/22 | 12/08/22 | 10/11/22 | 15/03/23 | 12/05/23 | 11/08/23 | 13/11/23 | 15/03/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | -12.7 | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 05/04/21 | 16/03/22 | 15/03/23 | 15/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.61% | 31.17M | |
+22.83% | 46.4B | |
-1.44% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.07% | 26.01B | |
-19.90% | 19.52B | |
+26.79% | 12.43B | |
+0.23% | 12.18B | |
-0.35% | 12.13B |
- Stock Market
- Equities
- ACXP Stock
- Financials Acurx Pharmaceuticals, Inc.